Nelson Jen An Chao

New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT

The Precision-T phase 3 trial is the first randomized, multicenter demonstration that a centrally manufactured defined allograft is effective markedly reducing moderate-to-severe chronic GVHD and non-relapse mortality without loss of graft versus leukemia or graft failure and inf...

You Are Already Trained for This: The Hematologist/Oncologist's Role in Radiation Mass Casualty Response

A large-scale radiation injury or nuclear incident requires an immediate, coordinated medical response that vastly exceeds traditional disaster management frameworks. While specialized networks exist, the initial surge of casualties will inevitably place a heavy burden on regiona...